Treatment of hepatitis B and C virus infection;Therapie der hepatitis-B- und -C-virusinfektion

Deutsche Medizinische Wochenschrift

Volumn 128, Issue SUPPL. 2, 2003, Pages

  Trautwein, C ^a   Tacke, F ^a  

^a HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ADEFOVIR; ADEFOVIR DIPIVOXIL; ALPHA INTERFERON; ENTECAVIR; HEPATITIS B SURFACE ANTIGEN; HEPATITIS B(E) ANTIGEN; LAMIVUDINE; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; RECOMBINANT ALPHA2A INTERFERON; RIBAVIRIN; TENOFOVIR;

ALGORITHM; BACTERIAL INFECTION; CONFERENCE PAPER; DRUG CONTRAINDICATION; HEPATITIS B; HEPATITIS B VIRUS; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; LABORATORY DIAGNOSIS; LIVER CIRRHOSIS; NEUTROPENIA; PATIENT COMPLIANCE; RELAPSE; SEROCONVERSION; THROMBOCYTOPENIA;

ANTIVIRAL AGENTS; HEPATITIS B; HEPATITIS C; HUMANS; PROGNOSIS;

EID: 0038606969     PISSN: 00120472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (18)

1. Bock CT, Tillmann HL, Torresi J et al. Selection of hepatitis B virus polymerase mutants with enhanced replication by lamivudine treatment after liver transplantation. Gastroenterology 2002; 122: 264-273
2. Dienstag JL, Goldin RD, Heathcote EJ et al. Histological outcome during long-term lamivudine therapy. Gastroenterology 2003; 124: 105-117
3. EASL international consensus conference on hepatitis B. Consensus statement. J Hepatol 2003; 38: 533-540
4. Fried MW, Shiffman ML, Reddy KR et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002; 347: 975-982
5. Hadziyannis SJ, Cheinquer H, Morgan T et al. Peginterferon alfa-2a (40KD) (pegasys) in combination with ribavirin (RBV): Efficacy and safety results from a phase III, randomized, double-blind, multicentre study examining effect of duration of treatment and RBV dose. J Hepatol 2002; 36: S1
6. Hadziyannis SJ et al. Adefovir dipivoxil for the treatment of hepatitis B e antigen-negative chronic hepatitis B. N Engl J Med 2003; 348: 800-807
7. Jäckel E, Cornberg M, Wedemeyer H et al. Treatment of acute hepatitis C with interferon alfa-2b. N Engl J Med 2001; 345: 1452-1457
8. Manesis EK, Hadziyannis SJ. Interferon alpha treatment and retreatment of hepatitis B e antigen-negative chronic hepatitis B. Gastroenterology 2001; 121: 101-109
9. Manns MP et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001; 358: 958-965
10. Marcellin P, Chang TT, Lim SG et al. Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B. N Engl J Med 2003; 348: 808-816
11. McHutchison JG, Manns MP, Patel K et al. Adherence to combination therapy enhances sustained response in genotype-1-infected patients with chronic hepatitis C. Gastroenterology 2002; 123: 1061-1069
12. Nafa S, Ahmed S, Tavan D et al. Early detection of viral resistance by determination of hepatitis B virus polymerase mutations in patients treated by lamivudine for chronic hepatitis B. Hepatology 2000; 32: 1078-1088
13. National Institutes of Health Consensus Development Conference Statement. Management of hepatitis C: 2002. Hepatology 2002; 36: S3-S20
14. Perrillo R, Schiff E, Yoshida E et al. Adefovir dipivoxil for the treatment of lamivudine-resistant hepatitis B mutants. Hepatology 2000; 32: 129-134
15. Shiffman ML Retreatment of patients with chronic hepatitis C. Hepatology 2002; 36: S128-134
16. Tillmann HL et al. Early lamivudine therapy may prevent liver failure in patients with fulminant hepatitis B. Hepatology 2002; 36: 375A
17. Trautwein C, Manns MP. Antivirale Therapie der Virushepatitis. Internist 2001; 42: 913-923
18. Wiese M et al. Low frequency of cirrhosis in a hepatitis C (genotype 1b) single-source outbreak in germany. Hepatology 2000; 32: 91-96